perifosine has been researched along with niacinamide in 5 studies
| Studies (perifosine) | Trials (perifosine) | Recent Studies (post-2010) (perifosine) | Studies (niacinamide) | Trials (niacinamide) | Recent Studies (post-2010) (niacinamide) |
|---|---|---|---|---|---|
| 245 | 31 | 140 | 13,381 | 1,097 | 5,797 |
| Protein | Taxonomy | perifosine (IC50) | niacinamide (IC50) |
|---|---|---|---|
| Chain A, NAD-dependent deacetylase | Thermotoga maritima | 1000 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 3.3 | |
| NAD-dependent protein deacetylase sirtuin-2 | Homo sapiens (human) | 2.9 | |
| NAD-dependent protein deacetylase sirtuin-3, mitochondrial | Homo sapiens (human) | 8.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samlowski, W; Vogelzang, NJ; Weissman, A | 1 |
| Anichini, A; Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Mortarini, R | 1 |
| Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D | 1 |
| Anichini, A; Carlo-Stella, C; Corradini, P; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Giordano, L; Guidetti, A; Locatelli, SL; Malorni, W; Marchianò, A; Mortarini, R; Russo, D; Sorasio, R; Viviani, S | 1 |
| Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW | 1 |
1 trial(s) available for perifosine and niacinamide
| Article | Year |
|---|---|
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Sorafenib; Treatment Outcome; Young Adult | 2014 |
4 other study(ies) available for perifosine and niacinamide
| Article | Year |
|---|---|
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2009 |
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Mitogen-Activated Protein Kinases; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured | 2013 |
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Proliferation; DNA Transposable Elements; Drug Synergism; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Sorafenib; Tumor Suppressor Protein p53 | 2015 |